GPER1 activation inhibits melanoma proliferation in both human and murine melanoma cell lines and induces c-Myc depletion, which is associated with reduced PD-L1 expression, potentially enhancing the response to immune checkpoint inhibitor therapies [36, 37]. Here, GPER1 is linked to melanoma.